This guideline is undergoing copyediting and the final version is expected to be released summer 2020.
This document is a practice guideline from the American Psychiatric Association for the treatment of patients with schizophrenia. It lists a guideline writing group, systematic review group, committee on practice guidelines, and APA assembly liaisons.
Its table of contents covers assessment and treatment planning, pharmacotherapy, antipsychotic medications, clozapine, long-acting injectable antipsychotics, and treatments for medication side effects such as dystonia, parkinsonism, akathisia, and tardive dyskinesia. The opening page states that this guideline is undergoing copyediting and the final version is expected to be released summer 2020.
It is the American Psychiatric Association practice guideline for the treatment of patients with schizophrenia.
George A. Keepers, M.D.
Assessment, pharmacotherapy, antipsychotic medications, clozapine, long-acting injectable antipsychotics, and treatments for side effects such as dystonia, parkinsonism, akathisia, and tardive dyskinesia.
It is undergoing copyediting and the final version is expected to be released summer 2020.